Beyond the Data: Translating CLL Evidence into Pharmacist-Led Recommendations
November 11, 2026
5:30 pm
Upcoming
Beyond the Data: Translating CLL Evidence into Pharmacist-Led Recommendations
November 12, 2026
5:30 pm
Upcoming
Menin Inhibitors in Relapsed/Refractory AML: Optimizing Selection, Safety, and Access
November 17, 2026
5:30 pm
Upcoming
Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care
November 17, 2026
5:30 pm
Upcoming
Menin Inhibitors in Relapsed/Refractory AML: Optimizing Selection, Safety, and Access
November 18, 2026
5:30 pm
Upcoming
Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care
November 19, 2026
5:30 pm
Upcoming
Menin Inhibitors in Relapsed/Refractory AML: Optimizing Selection, Safety, and Access
November 19, 2026
5:30 pm
Upcoming
Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care
November 19, 2026
5:30 pm
Upcoming
CLL Practice in Focus: Pharmacist Perspectives on BTK Inhibitor Therapy Across Community and Academic Settings
December 1, 2026
5:30 pm
Upcoming
Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care
December 1, 2026
5:30 pm
Upcoming
Beyond the Data: Translating CLL Evidence into Pharmacist-Led Recommendations
December 2, 2026
5:30 pm
Upcoming
Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care
December 2, 2026
5:30 pm
Upcoming